Skip to content

Treatment of Skin eruptions by Unani medicine Habb e Musaffi Khoon

Clinical Validation of Unani Pharmacopoeial Formulation Hab-e-Musaffi Khoon in Busoor-e-Jild (Skin Eruptions)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018087
Enrollment
240
Registered
2019-03-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R21- Rash and other nonspecific skin eruption

Interventions

Intervention1: Hab-e-Musaffi Khoon: Oral Adult: 4 pills (each 80mg) Daily To be taken with water for two weeks Control Intervention1: Nil: Nil

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The following criteria will be strictly followed for inclusion of cases in an observational study. 1. Patients of either sex in the age group of 15 to 60 years. 2. Occurrence of the following (5-15 in number): i. Vesicles (a vesicle is a small blister, as on the skin. Vesicles are less than 0.5 centimeters in diameter) ii. Papules (Small solid rounded bumps rising from the skin that are each usually less than 1 centimeter in diameter (less than 3/8 inch across) iii. Pustules (Small solid rounded bumps rising from the skin that are each usually less than 1 centimeter in diameter (less than 3/8 inch across) iv. Macules (Flat , distinct, colored area of the skin less than 1 cm in diameter)

Exclusion criteria

Exclusion criteria: The patients of Busoor-e-Jild (Skin Eruptions) with following conditions will be excluded from the study: 1. Age 60 years 2. Pregnancy and Lactation 3. Patients with disorders requiring long term treatment 4. Patients with more than 15 skin eruptions 5. Size of skin eruption more than 1cm 6. Eruptions due to viral diseases (Chicken pox, Measles, Herpes) 7. Patients with other inflammatory skin conditions like localized abscess/ carbuncles/ boils.

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of Busoor-e-Jild (Skin Eruptions)Timepoint: Two weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026